Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from Enzene
Adalvo today announced the acquisition of a romiplostim biosimilar program referencing Nplate® from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.
Read original article on The Medical News →Related news
-
Ego Integrity vs. Despair in Psychosocial Development
United Kingdom
-
Ulcerative colitis burden across 7MM to exceed 2.36 million cases by 2035, forecasts GlobalData
United Kingdom
-
How a neurologist is rethinking stroke prevention for the longevity era
United Kingdom
-
Etsy Cracks Down on AI-Generated Content to Protect Buyers from Barrage of Slop
United Kingdom
-
Running distance is associated with how female runners distribute their daily energy expenditure
United Kingdom
-
A single sauna session sends immune cells surging through your body
United States
-
Autonomy vs. Shame and Doubt
United Kingdom
-
Animal and plant proteins show different associations with testosterone levels in men
United Kingdom